Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infant immune response after Synflorix versus Prevenar-13 vaccination
NL-OMON37981Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Oct 2011
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of 10-valent pneumococcal conjugate vaccine and Prevnar 13 in pneumococcal disease (2 cohorts), sponsored by National Institute for Public Health and the Environment. Primary endpoints: Cellular immune response for pneumococcal serotypes and Humoral immune response for pneumococcal serotypes. Started Oct 2011; status: active, not recruiting.
02
Drugs
10-valent pneumococcal conjugate vaccinePrevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON37981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37981.